Last reviewed · How we verify
NCT03383913
HRV-B for Symptom Management in Sickle Cell Patients
NA trial testing Heart Rate Variability Biofeedback in Sickle Cell Disease in 15 participants. Completed in 28 December 2018.
28 December 2018
Quick facts
| Lead sponsor | Prisma Health-Upstate |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 15 |
| Start date | 22 January 2018 |
| Primary completion | 28 December 2018 |
| Estimated completion | 28 December 2018 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Heart Rate Variability Biofeedback — full drug profile →
Conditions studied
- Sickle Cell Disease — all drugs for Sickle Cell Disease →
Sponsor
Prisma Health-Upstate — full company profile →
Who can join
10 and older, any sex, with Sickle Cell Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will test the hypothesis that Heart Rate Variability Biofeedback (HRV-B) restores autonomic balance and reduces pain and other symptoms among patients with sickle cell disease (SCD).The specific aims of this study are to: (1) conduct a randomized, wait list controlled, pilot intervention trial to determine whether HRV-B increases HRV coherence among SCD participants (minimum N of 30, up to 50 total); (2) determine whether HRV-B reduces pain, stress, fatigue, depression or insomnia among SCD participants; and (3) determine whether increases in HRV coherence are associated improvements in pain, stress, fatigue, depression, or sleep among study participants.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03383913
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Heart Rate Variability Biofeedback
Trials testing the same drug.
- NCT05627687 — Caring Relationships Expression Study · Phase 1, PHASE2 · completed
- NCT05224050 — Heart Rate Variability Biofeedback for Smoking Cessation Treatment · Phase 2 · completed
- NCT03235466 — A Prospective Trial of Behavioral Therapy for Chronic Cough · NA · unknown
- NCT03338036 — The Effectiveness of Biofeedback for Individuals With Long-term Post-concussive Symptoms · NA · completed
Other recruiting trials for Sickle Cell Disease
Currently open trials in the same condition.
- NCT07369024 — Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults · Phase 2 · recruiting
- NCT06016634 — Alendronate for Osteonecrosis in Adults With Sickle Cell Disease · Phase 2 · recruiting
- NCT06260891 — Zinc Supplementation in Sickle Cell Disease: A Precursor to the Think Zinc for Bones Trial · Phase 2 · recruiting
- NCT07222475 — Writing Relaxing Beats in Adolescents Who Have Sickle Cell Disease · NA · recruiting
- NCT07224360 — Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD) · Phase 2 · recruiting
Other Prisma Health-Upstate trials
Trials by the same sponsor.
- NCT07202039 — Electronic Cigarettes as a Harm Reduction Strategy Among People With Opioid Use Disorder on Buprenorphine · NA · not yet recruiting
- NCT07375212 — VAPorized Administration of Bumetanide for Outpatient Relief in Heart Failure · Phase 4 · withdrawn
- NCT07102615 — Intracervical Vasopressin · Phase 4 · recruiting
- NCT07101250 — Preoperative Acetazolamide · Phase 4 · recruiting
- NCT06874413 — Targeted Prehabilitation With Physical Exercise and Inspiratory Muscle Training for Elderly Frail Patients Prior to Vent · NA · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03383913 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Prisma Health-Upstate
- Last refreshed: 28 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03383913.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing